KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Income from Continuing Operations (2018 - 2025)

Castle Biosciences' Income from Continuing Operations history spans 7 years, with the latest figure at 2343000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 124.43% year-over-year to 2343000.0; the TTM value through Dec 2025 reached 24158000.0, down 232.41%, while the annual FY2025 figure was 24158000.0, 232.41% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 2343000.0 at Castle Biosciences, down from 501000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 9590000.0 in Q4 2024 and bottomed at 29204000.0 in Q1 2023.
  • The 5-year median for Income from Continuing Operations is 5592500.0 (2021), against an average of 8438000.0.
  • The largest annual shift saw Income from Continuing Operations plummeted 1039.38% in 2023 before it skyrocketed 471.71% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 13381000.0 in 2021, then tumbled by 54.08% to 20618000.0 in 2022, then soared by 87.49% to 2580000.0 in 2023, then surged by 471.71% to 9590000.0 in 2024, then plummeted by 124.43% to 2343000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Income from Continuing Operations are 2343000.0 (Q4 2025), 501000.0 (Q3 2025), and 4534000.0 (Q2 2025).